SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today announced the presentation of four research projects aimed at identifying small molecule inhibitors of select kinases as potential therapeutics for certain types of cancers and other disorders. Rigel scientists will give the presentations during poster sessions from April 16th to 18th (see list below) at the upcoming meeting of the American Association for Cancer Research in Los Angeles, California.
